Novel honeycomb gallo-silicate microspheres for rapid hemostasis of oral and maxillofacial wounds

新型蜂窝状硅酸微球用于口腔颌面部伤口快速止血

• 批准号: 9914640
• 负责人: Isabelle L Denry
• 金额: $ 19.31万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-01 至 2021-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9914640
• 关键词: Acute; Address; Aerobic; Alveolar periostitis; Amino Acids; Antibiotic Resistance; Area; Bacteria; Bacteriology; Biocompatible Materials; Biological Assay; Biometry; Blood Coagulation Disorders; Blood Platelets; Blood Vessels; Cells; Cellulose; Characteristics; Charge; Chemicals; Chemistry; Coagulation Process; Collagen; Complication; Development; Distal; Electrocoagulation; Emergency Situation; Ensure; Environment; Erythrocytes; Escherichia coli; Excision; Exhibits; Exposure to; Fibrin; Formulation; Gallium; Gelatin; Goals; Gram-Negative Bacteria; Hematology; Hemorrhage; Hemostatic Agents; Hemostatic function; Hospitals; Impaired healing; In Situ; In Vitro; Infection prevention; Ion Exchange; Ions; Laboratories; Link; Literature; Lithium; Microbiology; Microspheres; Military Personnel; Minimum Inhibitory Concentration measurement; Monitor; Natural regeneration; Oral; Oral Surgical Procedures; Outcome; Oxides; Particle Size; Pathway interactions; Patients; Plants; Platelet aggregation; Polysaccharides; Postoperative Hemorrhage; Pre-hospitalization care; Process; Production; Property; Protocols documentation; Pseudomonas aeruginosa; Regulation; Reporting; Research Personnel; Risk; Role; Saliva; Silicates; Site; Sodium; Staphylococcus aureus; Streptococcus; Streptococcus anginosus; Streptococcus mitis; Streptococcus pyogenes; Structure; Surface; Surgical Blood Loss; Surgical sutures; Testing; Thrombin; Thrombosis; Thrombus; Time; Tissue Preservation; Tissues; Topical Antibiotic; Tourniquets; Ursidae Family; Work; Zeolites; acute infection; aggregation factor; antimicrobial; antimicrobial drug; bacterial metabolism; base; biomaterial compatibility; chronic infection; clay; cost; innovation; maxillofacial; microbiota; multidisciplinary; novel; oral surgery specialty; pathogen; physical property; prevent; stem; success; three dimensional structure; viral transmission; wound; wound healing; zeta potential

Hemorrhages in the highly vascularized oral and maxillofacial region are not amenable to control by tourniquet placement and often require the use of Topical Hemostatic Agents (THAs). THAs are commonly used to control severe bleeding, this is the case in both military and civilian pre-hospital care. The need for controlling hemostasis is even greater in patients undergoing antithrombotic therapy or suffering from bleeding disorders. Meanwhile, oral wounds and extraction sites are exposed to the rich microflora present in saliva, which can induce acute or chronic infections that delay healing, and are complicated by the rise of antibiotic-resistant species. THAs that are also antimicrobial would prevent these complications. Our laboratory recently discovered a new class of high surface area, honeycomb silicate microsphere framework (SMF) absorbents that prompt rapid hemostasis. Building on this discovery, our long-term goal is to develop fast-action, topical hemostatic and antimicrobial agents using honeycomb SMFs exchanged with gallium, which will further strengthen hemostatic efficacy and ensure antimicrobial activity. The antimicrobial efficacy of exogenously supplied gallium (in the form of Ga3+) to bacterial cells relies on its ability to replace Fe3+, thereby perturbing bacterial metabolism. Concurrently, based on the literature, we hypothesize that the reported hemostatic action of ionic gallium relies on its ability to flocculate fibrin. The expertise of our multidisciplinary team in silicate chemistry, materials chemistry, hematology, and microbiology will be leveraged to develop gallium-exchanged SMFs (Ga-SMFs). The project will initiate with the synthesis and characterization of SMFs (Aim 1), including their hemostatic efficacy as well as the mechanisms by which they promote hemostasis. Gallo-silicate microsphere frameworks (Ga-SMFs) will be produced by ion-exchange (Aim 2). Physical properties, gallium release profiles, biocompatibility and hemostatic efficacy will be characterized, and mechanisms by which gallium ion enhances hemostasis will be investigated. Finally, the antimicrobial efficacy will be tested against a panel of relevant bacteria. Direct deliverables are a new class of antimicrobial THAs with dual hemostatic action, triggering rapid hemostasis and preventing infections, that could bear applications well beyond oral and maxillofacial post-surgical hemorrhages.

高度血管化的口腔和上颌面区的出血不适合 通过止血带放置控制，通常需要使用局部止血剂（THAS）。 THA通常用于控制严重的出血，军事和平民都是这种情况 院前护理。在接受止血的需要更大的患者的需求更大 抗血栓疗法或患有出血性疾病的患者。同时，口腔伤口和 提取部位暴露于唾液中存在的富菌群，可能诱发急性或 延迟愈合的慢性感染，并因抗生素的兴起而复杂 物种。也是抗菌剂的ThA会阻止这些并发症。我们的实验室 最近发现了一类新的高表面积，Honeycomb硅酸盐微球框架 （SMF）引起快速止血的吸收。在这一发现的基础上，我们的长期目标是 使用蜂窝SMFS开发快速动作，局部止血和抗菌剂 与甘露交换，这将进一步增强止血功效并确保抗菌素 活动。外源提供的甘油（Ga3+的形式）的抗菌功效至 细菌细胞依赖其替代Fe3+的能力，从而扰乱细菌代谢。 同时，根据文献，我们假设报道的离子止血作用 甘露依靠其絮凝纤维蛋白的能力。硅酸盐的多学科团队的专业知识 化学，材料化学，血液学和微生物学将被利用以发展 炮交换的SMFS（GA-SMFS）。该项目将通过合成和 SMF的表征（AIM 1），包括其止血功效以及机制 他们通过其中促进止血。 Gallo-Silicate微球框架（GA-SMF）将是 由离子交换产生（AIM 2）。物理特性，镀耐型剖面，生物相容性 将表征和止血功效，以及炮离子增强的机制 将研究止血。最后，将针对一个面板测试抗菌功效 相关细菌。直接可交付成果是一类新的抗菌素，带有双重止血 动作，引发快速止血和预防感染，可以很好地应用应用 超越口腔和颌面后出血。